|
Published by: Wall Street Transcript
Published: Jun. 23, 2008 - 84 Pages
Table of Contents
- Biotechnology and Orthopedics Report - 84 pages of exclusive interviews, featuring:
- Roundtable Forum: Kevin DeGeeter, Oppenheimer & Co. Inc.; George Huang, Stansberry & Associates; Shivpreet Singh Kapoor, Ferris, Baker Watts Incorporated
- Small & Mid-Cap Biotech Companies - Dr. Simos Simeonidis, Broadpoint Capital
- Direct-Acting AntiVirals & Hepatitis C - Liisa Bayko, JMP Securities LLC
- Orthopedics: Spinal Segment - Ben Andrew, William Blair & Company, LLC
- Minimally Invasive Spine Surgical Outlook - John Putnam, Dawson James Securities, Inc.
- CEO Interviews - Amarillo Biosciences, Inc., Cleveland BioLabs, Inc., Encorium Group, Inc., Hemispherx Biopharma, Inc., Living Cell Technologies Limited, MannKind Corporation, Maxygen, Inc., Nabi Biopharmaceuticals, Opexa Therapeutics, Inc., Provectus Pharmaceuticals, Inc., SciClone Pharmaceuticals, Inc., Stellar Pharmaceuticals Inc., Vitro Diagnostics, Inc.
- Topics covered include: FDA approval process - Failures in oncology trials - Safety concerns - Public and private funding - PIPES and structured financing - Big Pharma partnerships - Development stage companies - Late-stage product companies - Technology platform companies - Outsourcing trends & CRO - Outlook for oncology companies - Urology companies and latest developments - Stock recommendations - Stocks to worry about
- Companies mentioned include: Genentech (DNA); ZymoGenetics ZGEN); AEterna Zentaris (AEZS); Sequenom (SQNM); ImmunoGen (IMGN); Genzyme (GENZ); Alnylam Pharmaceuticals (ALNY); Isis Pharmaceuticals (ISIS); Arena Pharmaceuticals (ARNA); Vertex Pharmaceuticals (VRTX); Progenics Pharmaceuticals (PGNX); Myriad Genetics (MYGN); Synta (SNTA)
AbstractThe Wall Street Transcript has just published its Biotechnology and Orthopedics issue, a report offering a timely review of the sector to serious investors and industry executives. This 84page feature contains industry commentary through in depth an expert roundtable, in depth interviews with 4 Industry Analyst and CEOs from 13 sector firms.
Topics covered include:
FDA approval process
Failures in oncology trials
Safety concerns
Public and private funding
PIPES and structured financing
Big Pharma partnerships
Development stage companies
Latestage product companies
Technology platform companies
Outsourcing trends & CRO
Outlook for oncology companies
Urology companies and latest developments
Stock recommendations
Stocks to worry about
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
|
About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.
© MarketResearch.com 2008
|